New combo therapy shows promise for untreatable liver cancer
NCT ID NCT07204327
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at how well a combination of two drugs (atezolizumab and bevacizumab) plus local treatments like chemo or radiation works for people with advanced liver cancer that can't be removed by surgery. About 1,136 patients from hospitals in China and Asia will be included. The goal is to see if this approach helps people live longer and controls the cancer better.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for UNRESECTABLE HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Zhongda Hospital, Southeast University
Nanjing, Jiangsu, 210009, China